MRN Selects Resiliélle® Age Zero™ Exosomes as Gold Standard in Regenerative Aesthetics

AVON, Conn. - EntSun -- MedResults Network (MRN), one of the nation's largest group purchasing organizations for aesthetic and surgical practices, has named Resiliélle® Age Zero™ Exosomes as its exclusive exosome partner following a multi-year nationwide search.

After visiting eight laboratories and evaluating data, leadership, and manufacturing processes, MRN President and CEO Jeff Routledge confirmed Resiliélle's Age Zero™ platform as the most advanced and scientifically validated exosome solution for medical aesthetics.

"In a marketplace filled with questionable claims, one company stood above the rest," said Routledge. "Resiliélle Age Zero™ Exosomes are fully characterized, verified through independent testing at a Harvard Medical School Core Laboratory, and represent the true medical-grade standard in regenerative aesthetics."

Independent testing has shown that most exosome products on the market contain few or no intact exosomes. In contrast, through independent laboratory testing, Resiliélle® Age Zero™ Exosomes have demonstrated structurally intact bilipid membranes with verified internal cargo, confirmed through Transmission Electron Microscopy (TEM), Immunogold staining, NanoSight NS300 analysis, CD marker profiling, and proteomic characterization. Each batch is third-party tested in CLIA-certified U.S. laboratories to ensure quality, consistency, and verified bioactivity.

More on EntSun News

• Julie Colombino-Billingham Hosts Book Launch & Boutique Benefit for Haiti & Jamaica Recovery
• 6 Holiday Looks That Scream "Old Money" But Cost Less Than Your Christmas Tree
• Touch Massage London Unveils Premium Local Massage Services to Transform Wellbeing Across the Capital
• Joseph Neibich: Crafting Comedy from Hollywood Chaos
• From Cheer to Courtroom: The Hidden Legal Risks in Your Holiday Eggnog

"Together with Resiliélle, we'll bring real science and education to our members," added Routledge. "Our goal is to educate providers on the importance of verified exosomes and how they can safely enhance aesthetic outcomes."

This partnership makes Resiliélle Age Zero™ Exosomes available to over 4,000 MRN member practices nationwide.

"We're honored to partner with MedResults Network," said Michael C. Crowley, JD, Chairman of Resiliélle. "Together, we'll expand access to verified, bioactive exosomes and help aesthetic providers deliver safer, more effective regenerative treatments."

Resiliélle®, co-led by Michael Crowley and his daughter Erin Crowley, M.Eng., together with their team of scientists and engineers, combines over a century of stem cell and exosome research with patent-pending manufacturing technologies to produce the world's most fully characterized exosome platform, which is supported by a commercial team with decades of experience in the aesthetic industry.

For more information, visit medresultsnetwork.com/introducing-resilielle-age-zero-exosomes.

More on EntSun News

• JRP Virtual Celebrates Alexis Knapp as Former Talent Secures New Role in Upcoming Sci-Fi Film
• Lior Selve to Star in Christmas at Mistletoe Manor on Great American Family, Premiering December 7th
• "Great American Family to Premiere Christmas at Mistletoe Manor
• Controversial Vegan Turns Rapper Launches First Song, "Psychopathic Tendencies."
• Inside the Fight for Affordable Housing: Avery Headley Joins Terran Lamp for a Candid Bronx Leadership Conversation

About MedResults Network

Founded in 2008, MRN is a leading Group Purchasing Organization serving over 4,000 aesthetic practices and medspas nationwide. MRN connects members to vetted vendors and exclusive partnerships that drive compliance, safety, and savings.

About Resiliélle®

RESILIÉLLE COSMETICS LLC located in Rochester, NY is redefining regenerative aesthetics with its Age Zero™ Exosomes. Backed by 20+ years of stem cell and hematology research, Resilielle has pioneered the world's most fully characterized, medically validated exosome platform. Resilielle combines regulatory integrity, clinical science, and patent-pending manufacturing to set the global benchmark for exosome-based aesthetics.